Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Exciting novel treatments being developed for MDS

Lionel Ades • 2 Jun 2020
EHA 2020
Myelodysplastic Syndromes Antibodies Checkpoint inhibitors Pembrolizumab Pevonedistat Venetoclax

Lionel Ades, MD, PhD, Avicenne Hospital, Bobigny, France, talks on exciting novel treatments being developed for myelodysplastic syndromes (MDS). Specifically discussed is the combination of hypomethylating agents with new agents such as those inhibiting IDH1 and IDH2 as well as the use of agents such as venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lionel Ades

Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more
5:17
Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more
Andrew Brunner et al. • 28 Jun 2025
High-risk MDS: pevonedistat and azacitidine vs azacitidine alone
3:05
High-risk MDS: pevonedistat and azacitidine vs azacitidine alone
Lionel Ades • 2 Jun 2020
The current challenges facing high-risk MDS treatment
0:59
The current challenges facing high-risk MDS treatment
Lionel Ades • 1 Jun 2020

Related Videos

Proposed updates to AML classification: implications for clinical trials and practice
23:33
Proposed updates to AML classification: implications for clinical trials and practice
Robert Hasserjian • 18 Sep 2026
Current challenges and future strategies for TP53-mutated AML and MDS
13:28
Current challenges and future strategies for TP53-mutated AML and MDS
Maximilian Stahl • 20 Sep 2026
Novel targets in AML and their implications for clinical practice
12:14
Novel targets in AML and their implications for clinical practice
Sanam Loghavi • 20 Sep 2026
Clinical considerations for CHIP/CCUS detection, risk stratification and intervention
14:47
Clinical considerations for CHIP/CCUS detection, risk stratification and intervention
Uma Borate • 19 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals